Through a back door

Funxional Therapeutics Ltd. believes its small molecule broad-spectrum chemokine inhibitors can provide advantages over current treatments for inflammatory and autoimmune diseases. The first test for lead compound FX125L will be whether it can provide similar efficacy and improved safety versus corticosteroids in asthma.

Earlier this month, the compound was shown to be well tolerated in a Phase I trial...